中华临床医师杂志（电子版）
中華臨床醫師雜誌（電子版）
중화림상의사잡지（전자판）
CHINESE JOURNAL OF CLINICIANS(ELECTRONIC VERSION)
2014年
11期
1997-2001
,共5页
饶明月%吴敬波%林盛%张振华%刘巧俐%王丽英
饒明月%吳敬波%林盛%張振華%劉巧俐%王麗英
요명월%오경파%림성%장진화%류교리%왕려영
卵巢肿瘤%药物疗法%肿瘤深部热疗
卵巢腫瘤%藥物療法%腫瘤深部熱療
란소종류%약물요법%종류심부열료
Ovarian neoplasms%Drug therapy%Deep hyperthermia
目的：探讨深部热疗联合全身化疗治疗晚期卵巢癌的临床近期疗效与相关毒副反应。方法将73例晚期卵巢癌患者随机分为深部热疗联合全身化疗组（治疗组）36例和单纯全身化疗组（对照组）37例，均给予紫杉醇＋顺铂/卡铂方案化疗，热疗为腹盆腔深部热疗。治疗结束时，评价两组近期疗效，并观察毒副反应。结果治疗组和对照组的有效率及临床受益率分别是63.4%vs.51.4%（P＝0.279），80.6%vs.70.3%（P＝0.308）；总有效率比较为77.8%vs.56.8%（P＝0.056）；CA125下降率分别为72.2%vs.54.1%（P＝0.108），均无显著性差异。腹水控制率分别为70.6%vs.38.9%（P＝0.044），差异有统计学意义。两组毒副反应主要是骨髓抑制、胃肠道反应、脱发、神经毒性等，大多为Ⅱ～Ⅲ度。治疗组及对照组发生Ⅲ＋Ⅳ度骨髓抑制、胃肠道反应分别为38.9% vs.45.9%、19.4%vs.27.0%，差异无统计学意义（P＝0.922，P＝0.425）。热疗副反应轻，表现为轻度烫伤，不增加化疗的副作用。结论深部热疗联合全身化疗能一定程度提高晚期卵巢癌近期疗效，可缓解患者腹水引起的腹胀等临床症状，治疗相关毒副反应可耐受。
目的：探討深部熱療聯閤全身化療治療晚期卵巢癌的臨床近期療效與相關毒副反應。方法將73例晚期卵巢癌患者隨機分為深部熱療聯閤全身化療組（治療組）36例和單純全身化療組（對照組）37例，均給予紫杉醇＋順鉑/卡鉑方案化療，熱療為腹盆腔深部熱療。治療結束時，評價兩組近期療效，併觀察毒副反應。結果治療組和對照組的有效率及臨床受益率分彆是63.4%vs.51.4%（P＝0.279），80.6%vs.70.3%（P＝0.308）；總有效率比較為77.8%vs.56.8%（P＝0.056）；CA125下降率分彆為72.2%vs.54.1%（P＝0.108），均無顯著性差異。腹水控製率分彆為70.6%vs.38.9%（P＝0.044），差異有統計學意義。兩組毒副反應主要是骨髓抑製、胃腸道反應、脫髮、神經毒性等，大多為Ⅱ～Ⅲ度。治療組及對照組髮生Ⅲ＋Ⅳ度骨髓抑製、胃腸道反應分彆為38.9% vs.45.9%、19.4%vs.27.0%，差異無統計學意義（P＝0.922，P＝0.425）。熱療副反應輕，錶現為輕度燙傷，不增加化療的副作用。結論深部熱療聯閤全身化療能一定程度提高晚期卵巢癌近期療效，可緩解患者腹水引起的腹脹等臨床癥狀，治療相關毒副反應可耐受。
목적：탐토심부열료연합전신화료치료만기란소암적림상근기료효여상관독부반응。방법장73례만기란소암환자수궤분위심부열료연합전신화료조（치료조）36례화단순전신화료조（대조조）37례，균급여자삼순＋순박/잡박방안화료，열료위복분강심부열료。치료결속시，평개량조근기료효，병관찰독부반응。결과치료조화대조조적유효솔급림상수익솔분별시63.4%vs.51.4%（P＝0.279），80.6%vs.70.3%（P＝0.308）；총유효솔비교위77.8%vs.56.8%（P＝0.056）；CA125하강솔분별위72.2%vs.54.1%（P＝0.108），균무현저성차이。복수공제솔분별위70.6%vs.38.9%（P＝0.044），차이유통계학의의。량조독부반응주요시골수억제、위장도반응、탈발、신경독성등，대다위Ⅱ～Ⅲ도。치료조급대조조발생Ⅲ＋Ⅳ도골수억제、위장도반응분별위38.9% vs.45.9%、19.4%vs.27.0%，차이무통계학의의（P＝0.922，P＝0.425）。열료부반응경，표현위경도탕상，불증가화료적부작용。결론심부열료연합전신화료능일정정도제고만기란소암근기료효，가완해환자복수인기적복창등림상증상，치료상관독부반응가내수。
Objective To investigate the clinical near-term therapeutic effect and toxicity of deep hyperthermia combined with chemotherapy in advanced ovarian cancer. Methods A total of 73 patients with advanced ovarian cancer were randomly assigned to the deep hyperthermia combined with intravenous chemotherapy group (treatment group, n=36) and the intravenous chemotherapy group (control group, n=37). Both of groups were treated with paclitaxel and cisplatin/carboplatin intravenously, and treatment group was chemotherapy combined with abdominal and pelvic deep hyperthermia. At the end of treatment, the near-term curative effect and adverse reactions were observed. Results The efficiency and clinical benefit rates of two groups were 63.4% vs. 51.4% (P=0.279), 80.6% vs. 70.3% (P=0.308). The comparison of total efficiency was 77.8%vs. 56.8%(P=0.056) and CA125 decreased by 72.2%vs. 54.1%(P=0.108), respectively, the differences were not statistically significant. In the control of ascites, the effective rate of treatment group reached 70.6%, higher than 38.9%in the control group, the difference was statistically significant(P=0.044). The kinds of main toxicity were bone marrow suppression, gastrointestinal reaction, alopecia and neurotoxicity as grade Ⅱ-Ⅲ mostly in both groups. The incidence of Ⅲ+Ⅳ degree bone marrow suppression and gastrointestinal reaction were respectively 38.9% vs. 45.9%, 19.4% vs. 27.0%, but the differences were not statistically significant (P=0.922, P=0.425). Hyperthermia side-effect represented mild empyrosis, and did not increased the toxicity of chemotherapy. Conclusion Deep hyperthermia combined with intravenous chemotherapy could partially improved near-term curative effect in advanced ovarian cancer , especially could relieved abdominal distension and other clinical symptoms caused by ascites in patients, and treatment related toxicity could be tolerated.
